Evidence map›Paper›PMID 35743806›Full record

ArticleLife (Basel, Switzerland)2022

Exploring and Identifying Prognostic Phenotypes of Patients with Heart Failure Guided by Explainable Machine Learning.

Xue Zhou, Keijiro Nakamura, Naohiko Sahara, Masako Asami, Yasutake Toyoda, Yoshinari Enomoto, Hidehiko Hara, Mahito Noro, Kaoru Sugi, Masao Moroi and 3 more

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xue ZhouBiomedical Information Engineering Lab, The University of Aizu, Aizuwakamatsu 965-8580, Japan.
Keijiro NakamuraDivision of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.ORCID 0000-0002-1580-0890
Naohiko SaharaDivision of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.ORCID 0000-0002-7448-0903
Masako AsamiDivision of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.
Yasutake ToyodaDivision of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.
Yoshinari EnomotoDivision of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.
Hidehiko HaraDivision of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.
Mahito NoroDivision of Cardiovascular Medicine, Odawara Cardiovascular Hospital, Odawara 250-0873, Japan.
Kaoru SugiDivision of Cardiovascular Medicine, Odawara Cardiovascular Hospital, Odawara 250-0873, Japan.
Masao MoroiDivision of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.
Masato NakamuraDivision of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.ORCID 0000-0003-1463-3469
Ming HuangDivision of Information Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan.
Xin ZhuBiomedical Information Engineering Lab, The University of Aizu, Aizuwakamatsu 965-8580, Japan.ORCID 0000-0002-4376-0806

Funding

Japan Society for the Promotion of Science Kakenhi Basic Research Fund C 21K10287The University of Aizu 2021-P-5
6 · The paper itself

Abstract

Identifying patient prognostic phenotypes facilitates precision medicine. This study aimed to explore phenotypes of patients with heart failure (HF) corresponding to prognostic condition (risk of mortality) and identify the phenotype of new patients by machine learning (ML). A unsupervised ML was applied to explore phenotypes of patients in a derivation dataset (n = 562) based on their medical records. Thereafter, supervised ML models were trained on the derivation dataset to classify these identified phenotypes. Then, the trained classifiers were further validated on an independent validation dataset (n = 168). Finally, Shapley additive explanations were used to interpret decision making of phenotype classification. Three patient phenotypes corresponding to stratified mortality risk (high, low, and intermediate) were identified. Kaplan−Meier survival curves among the three phenotypes had significant difference (pairwise comparison p < 0.05). Hazard ratio of all-cause mortality between patients in phenotype 1 (n = 91; high risk) and phenotype 3 (n = 329; intermediate risk) was 2.08 (95%CI 1.29−3.37, p = 0.003), and 0.26 (95%CI 0.11−0.61, p = 0.002) between phenotype 2 (n = 142; low risk) and phenotype 3. For phenotypes classification by random forest, AUCs of phenotypes 1, 2, and 3 were 0.736 ± 0.038, 0.815 ± 0.035, and 0.721 ± 0.03, respectively, slightly better than the decision tree. Then, the classifier effectively identified the phenotypes for new patients in the validation dataset with significant difference on survival curves and hazard ratios. Finally, age and creatinine clearance rate were identified as the top two most important predictors. ML could effectively identify patient prognostic phenotypes, facilitating reasonable management and treatment considering prognostic condition.

Indexed as

heart failuremachine learningmortality riskpatient phenotypesprognosis

Identifiers

PMID35743806
PMCPMC9224610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.